TheStreet upgraded shares of Mylan (NASDAQ:MYL) from a c rating to a b- rating in a research report sent to investors on Wednesday.
MYL has been the topic of a number of other reports. Citigroup set a $42.00 target price on Mylan and gave the stock a buy rating in a report on Wednesday, October 4th. Zacks Investment Research raised Mylan from a sell rating to a hold rating in a research report on Tuesday. Guggenheim began coverage on Mylan in a research report on Tuesday, December 12th. They issued a buy rating and a $59.00 price target for the company. Wells Fargo & Co set a $43.00 price target on Mylan and gave the company a hold rating in a research report on Thursday. Finally, Instinet reissued a buy rating and issued a $37.00 price target on shares of Mylan in a research report on Thursday, October 5th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. Mylan currently has a consensus rating of Buy and an average target price of $44.19.
Shares of Mylan (MYL) traded up $0.22 on Wednesday, hitting $46.73. The company had a trading volume of 7,887,043 shares, compared to its average volume of 6,458,200. Mylan has a 12 month low of $29.39 and a 12 month high of $47.25. The company has a current ratio of 1.46, a quick ratio of 0.95 and a debt-to-equity ratio of 1.05. The company has a market cap of $24,950.00, a PE ratio of 28.15, a P/E/G ratio of 1.49 and a beta of 1.38.
Mylan (NASDAQ:MYL) last issued its earnings results on Monday, November 6th. The company reported $1.10 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.10). Mylan had a return on equity of 20.63% and a net margin of 7.28%. The firm had revenue of $2.99 billion during the quarter, compared to the consensus estimate of $3.09 billion. During the same quarter in the prior year, the business earned $1.38 earnings per share. Mylan’s revenue for the quarter was down 2.3% on a year-over-year basis. analysts anticipate that Mylan will post 4.56 earnings per share for the current fiscal year.
In other news, CEO Heather M. Bresch sold 75,000 shares of the firm’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $45.00, for a total transaction of $3,375,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.69% of the company’s stock.
Several institutional investors have recently made changes to their positions in the company. Lingohr & Partner Asset Management GmbH increased its position in shares of Mylan by 5.0% during the 4th quarter. Lingohr & Partner Asset Management GmbH now owns 22,979 shares of the company’s stock valued at $972,000 after purchasing an additional 1,100 shares during the last quarter. State of Alaska Department of Revenue increased its holdings in Mylan by 106.3% in the 4th quarter. State of Alaska Department of Revenue now owns 61,092 shares of the company’s stock worth $2,583,000 after acquiring an additional 31,480 shares during the last quarter. Oakbrook Investments LLC increased its holdings in Mylan by 72.2% in the 4th quarter. Oakbrook Investments LLC now owns 39,600 shares of the company’s stock worth $1,675,000 after acquiring an additional 16,600 shares during the last quarter. Charter Trust Co. purchased a new stake in Mylan in the 4th quarter worth about $226,000. Finally, Schwab Charles Investment Management Inc. increased its holdings in Mylan by 1.8% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 1,911,875 shares of the company’s stock worth $80,892,000 after acquiring an additional 33,772 shares during the last quarter. 74.90% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “Mylan (MYL) Upgraded to B- at TheStreet” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/19/mylan-myl-upgraded-to-b-at-thestreet.html.
Mylan Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.